Raymond James Financial Inc. bought a new stake in shares of BioNTech SE (NASDAQ:BNTX - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 5,122 shares of the company's stock, valued at approximately $584,000.
A number of other hedge funds have also recently bought and sold shares of BNTX. Bank of New York Mellon Corp raised its holdings in shares of BioNTech by 4.3% during the fourth quarter. Bank of New York Mellon Corp now owns 3,677 shares of the company's stock valued at $419,000 after acquiring an additional 150 shares during the period. Perigon Wealth Management LLC raised its stake in BioNTech by 3.9% during the 4th quarter. Perigon Wealth Management LLC now owns 5,902 shares of the company's stock valued at $666,000 after purchasing an additional 224 shares during the period. Atomi Financial Group Inc. raised its stake in BioNTech by 6.7% during the 4th quarter. Atomi Financial Group Inc. now owns 3,635 shares of the company's stock valued at $414,000 after purchasing an additional 229 shares during the period. Jones Financial Companies Lllp lifted its holdings in shares of BioNTech by 110.3% in the fourth quarter. Jones Financial Companies Lllp now owns 469 shares of the company's stock valued at $53,000 after purchasing an additional 246 shares in the last quarter. Finally, GAMMA Investing LLC boosted its position in shares of BioNTech by 48.2% in the fourth quarter. GAMMA Investing LLC now owns 923 shares of the company's stock worth $105,000 after buying an additional 300 shares during the period. 15.52% of the stock is owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
Several brokerages recently issued reports on BNTX. Truist Financial assumed coverage on BioNTech in a research note on Friday, January 10th. They issued a "buy" rating and a $172.00 price objective for the company. Citigroup began coverage on shares of BioNTech in a report on Thursday, March 13th. They set a "buy" rating and a $145.00 price target for the company. HC Wainwright dropped their price objective on shares of BioNTech from $150.00 to $145.00 and set a "buy" rating on the stock in a research note on Tuesday, April 1st. BMO Capital Markets lifted their target price on shares of BioNTech from $130.00 to $143.00 and gave the company an "outperform" rating in a research note on Tuesday, March 11th. Finally, Morgan Stanley dropped their price target on shares of BioNTech from $145.00 to $139.00 and set an "overweight" rating on the stock in a research note on Tuesday, March 11th. Three equities research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $143.44.
View Our Latest Report on BioNTech
BioNTech Stock Performance
BioNTech stock traded up $3.40 during trading hours on Friday, reaching $96.52. 1,149,784 shares of the company were exchanged, compared to its average volume of 854,764. BioNTech SE has a 12 month low of $76.53 and a 12 month high of $131.49. The company has a current ratio of 7.33, a quick ratio of 7.21 and a debt-to-equity ratio of 0.01. The stock has a 50-day moving average of $104.64 and a 200 day moving average of $111.67. The firm has a market cap of $23.16 billion, a price-to-earnings ratio of -45.96 and a beta of 1.07.
BioNTech (NASDAQ:BNTX - Get Free Report) last posted its quarterly earnings data on Monday, March 10th. The company reported $1.08 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.38 by $0.70. The business had revenue of $1.19 billion during the quarter, compared to the consensus estimate of $1.24 billion. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. BioNTech's quarterly revenue was down 19.5% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.90 EPS. As a group, research analysts anticipate that BioNTech SE will post -3.88 earnings per share for the current year.
BioNTech Profile
(
Free Report)
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.
Featured Stories
Before you consider BioNTech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioNTech wasn't on the list.
While BioNTech currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
